Show simple item record

dc.contributor.authorRutherford, Claudia
dc.contributor.authorPatel, Manish I
dc.contributor.authorTait, Margaret-Ann
dc.contributor.authorSmith, David P
dc.contributor.authorCosta, Daniel SJ
dc.contributor.authorSengupta, Shomik
dc.contributor.authorKing, Madeleine T
dc.description.abstractObjective: Non-muscle invasive bladder cancer (NMIBC) is a chronic condition requiring repeated treatment and endoscopic examinations that can occur life-long. In this context, patient-reported outcomes (PROs) are important considerations to patients and managing clinicians. We undertook a systematic review to synthesise PRO results relevant to NMIBC treatment to explore trajectories overtime and differences between treatment options. Methods: We searched databases AMED, MEDLINE, EMbase, PsycINFO, Web of Knowledge and Scopus (inception to 5th December 2019), reference lists and contacted key authors to identify studies that reported PROs after NMIBC treatment. Two reviewers independently applied inclusion and quality criteria and extracted findings. Results for PROs were synthesised for treatment groups across three time periods: acute/during induction therapy; during maintenance therapy; and long-term follow-up (> 1 year). Results: Of 3193 papers screened, 29 were eligible. These provided evidence about induction treatment effects, but few reported maintenance or long-term evidence, and evidence about differences between NMIBC treatment options was lacking. A range of symptoms (pain in bladder area, urinary frequency and urgency, pain or burning during urination) were commonly experienced during and soon after treatment for NMIBC. Less common symptoms included fatigue, disrupted sleep and gastrointestinal problems. Conclusions: Treatments for NMIBC can cause symptoms and functional impairment during the acute treatment phase and reduce quality of life. Clinicians should be aware of these impairments to prepare patients for short-term sequelae and enable those with treatment options to exercise preferences in choosing among them. However, gaps in current evidence limit our understanding of PRO trajectories from diagnosis through to long-term survivorship and treatment effects.en_US
dc.relation.ispartofjournalQuality of Life Researchen_US
dc.subject.fieldofresearchPublic Health and Health Servicesen_US
dc.subject.keywordsScience & Technologyen_US
dc.subject.keywordsLife Sciences & Biomedicineen_US
dc.subject.keywordsHealth Care Sciences & Servicesen_US
dc.subject.keywordsHealth Policy & Servicesen_US
dc.subject.keywordsPublic, Environmental & Occupational Healthen_US
dc.titlePatient-reported outcomes in non-muscle invasive bladder cancer: a mixed-methods systematic reviewen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Articlesen_US
dcterms.bibliographicCitationRutherford, C; Patel, MI; Tait, M-A; Smith, DP; Costa, DSJ; Sengupta, S; King, MT, Patient-reported outcomes in non-muscle invasive bladder cancer: a mixed-methods systematic review, Quality of Life Research, 2020en_US
gro.description.notepublicThis publication has been entered into Griffith Research Online as an Advanced Online Version.en_US
gro.hasfulltextNo Full Text
gro.griffith.authorSmith, David

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record